慢性肾脏病贫血患者心血管安全性问题探析

doi:10.3969/j.issn.1671-4091.2020.06.002

中国血液净化 ›› 2020, Vol. 19 ›› Issue (06): 364-367.doi: 10.3969/j.issn.1671-4091.2020.06.002

慢性肾脏病贫血患者心血管安全性问题探析

贾媛媛¹,金方霞¹,杜玄一¹

1哈尔滨医科大学附属第二医院肾内科

收稿日期:2020-02-25 修回日期:2020-03-16 出版日期:2020-06-12 发布日期:2020-06-24
通讯作者: 杜玄一dxy_shennei@126.com E-mail:dxy_shennei@126.com

Cardiovascular safety in CKD patients with anemia

1Department of Nephrology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China

Received:2020-02-25 Revised:2020-03-16 Online:2020-06-12 Published:2020-06-24
Contact: Xuan yiDU E-mail:dxy_shennei@126.com

摘要/Abstract

摘要： 【摘要】贫血是慢性肾脏病(chronic kidney disease，CKD)最常见的并发症之一。心血管疾病(cardiovascular disease, CVD)是CKD 3～5 期患者的首要致死原因。CKD 贫血能够加重多系统器官的损伤,是CKD 患者伴有心血管并发症的独立危险因素。因此，加强对CKD 患者贫血的管理，有利于改善CKD 患者的心血管结局。本文主要从CKD贫血本身以及治疗等方面对CKD 贫血患者的心血管安全问题进行综述。

关键词: 贫血, 慢性肾脏病, 心血管疾病, 罗沙司他

Abstract: 【Abstract】Anemia is one of the most common complications in chronic kidney disease (CKD) patients. Cardiovascular disease is a major cause of mortality in CKD patients at stage 3～5. Renal anemia can aggravate the multisystem organ damages and is an important independent risk factor for cardiovascular complications in CKD patients. Therefore, management of renal anemia must be emphasized to improve the cardiovascular outcome in CKD patients. This article reviews cardiovascular safety in CKD patients with anemia from the view point of renal anemia and its treatment.

Key words: Anemia, Chronic kidney disease, Cardiovascular disease, Roxadustat

中图分类号:

R453

贾媛媛, 金方霞, 杜玄一. 慢性肾脏病贫血患者心血管安全性问题探析[J]. 中国血液净化, 2020, 19(06): 364-367.

参考文献

[1] Tanaka K, Watanabe T, Takeuchi A, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease[J]. Kidney International,2017,91(1):227-234.
[2] Gansevoort R T D, Correa-Rotter R P, Hemmelgarn B R P, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention[J]. Lancet,2013,382(9889):339-352.
[3] 马春园，何樟秀，周阳，等。慢性肾脏病3 ～ 5D期贫血状况的单中心横断面调查[J]。中国血液净化,2017,17(4):205-210。
[4] Zhang L, Zuo L, Yu F, et al. China Kidney Disease Network (CK-NET) 2015 Annual Data Report[J]. Kidney Int Suppl,2019,9(1):e1–e81.
[5] Kim-Mitsuyama S, Soejima H, Yasuda O, et al. Anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients with well-controlled blood pressure: a subgroup analysis of the ATTEMPT-CVD randomized trial[J]. Hypertension Research,2019,42(6):883-891.
[6] Foley R N, Parfrey P S, Harnett J D, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease[J]. American Journal of Kidney Diseases,1996,28(1):53-61.
[7] Tanaka T, Eckardt K. HIF Activation Against CVD in CKD: Novel Treatment Opportunities[J]. Seminars in Nephrology,2018,38(3):267-276.
[8] Singh A K, Szczech L, Tang K L, et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease[J]. The New England Journal of Medicine,2006,355(20):2085-2098.
[9] Mccullough P A, Barnhart H X, Inrig J K, et al. Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney Disease[J]. American Journal of Nephrology,2013,37(6):549-558.
[10] Zhang Y, Thamer M, Stefanik K, et al. Epoetin requirements predict mortality in hemodialysis patients[J]. American Journal of Kidney Diseases,2004,44(5):866-876.
[11] Vaziri N D. Safety Issues in Iron Treatment in CKD[J]. Seminars in Nephrology,2016,36(2):112-118.
[12] Agarwal R, Kusek J W, Pappas M K. A randomized trial of intravenous and oral iron in chronic kidney disease[J]. Kidney International,2015,88(4):905-914.
[13] Tangri N, Miskulin D C, Zhou J, et al. Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study[J]. Nephrol Dial Transplant,2015,30(4):667-675.
[14] H?lscher M, Silter M, Krull S, et al. Cardiomyocyte-specific Prolyl-4-hydroxylase Domain 2 Knock Out Protects from Acute Myocardial Ischemic Injury[J]. Journal of Biological Chemistry,2011,286(13):11185-11194.
[15] Chaudhari S M, Sluimer J C, Koch M, et al. Deficiency of HIF1α in Antigen-Presenting Cells Aggravates Atherosclerosis and Type 1 T-Helper Cell Responses in Mice[J]. Arteriosclerosis, Thrombosis, and Vascular Biology,2015,35(11):2316-2325.
[16] Zhang X, Zhang Y, Wang P, et al. Adipocyte Hypoxia-Inducible Factor 2α Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism[J]. Cell Metabolism,2019,30(5):937-951.
[17] Hwang S, Nguyen A D, Jo Y, et al. Hypoxia-inducible factor 1alpha activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver[J]. J Biol Chem,2017,292(22):9382-9393.
[18] Locatelli F, Fishbane S, Block G A, et al. Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients[J]. American Journal of Nephrology,2017,45(3):187-199.
[19] Akizawa T, Tsubakihara Y, Nangaku M, et al. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects[J]. American Journal of Nephrology,2017,45(2):127-135.
[20] Martin E R, Smith M T, Maroni B J, et al. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease[J]. American Journal of Nephrology,2017,45(5):380-388.

慢性肾脏病贫血患者心血管安全性问题探析

Cardiovascular safety in CKD patients with anemia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	许世林, 刘云, 谭荣韶, 黎淑婷, 邹得娥, 鲍敏锐, 粱威锋, 陈文璇, 刘岩, 钟小仕. 维持性血液透析患者较低的全血锌与贫血独立相关[J]. 中国血液净化, 2020, 19(10): 678-682.
[2]	刘雪姣谢晓东程虹陈文梅陈岚卞维静. 甲状旁腺增生在维持性血液透析患者全因死亡和主要不良心脏事件中的作用[J]. 中国血液净化, 2020, 19(09): 592-597.
[3]	李赞, 周树录. 维生素D 受体TaqI 基因多态性与慢性肾脏病透析患者预后的关系[J]. 中国血液净化, 2020, 19(06): 372-375.
[4]	高建军, 蔡广研. 肾性贫血的负担[J]. 中国血液净化, 2020, 19(06): 361-363.
[5]	陈吉林, 林洪丽. 慢性肾脏病患者铁缺乏及铁代谢[J]. 中国血液净化, 2020, 19(06): 368-371.
[6]	彭琼瑶, 谢树钦, 马宁, 刘玲. 血清骨硬化蛋白水平与尿毒症患者血管钙化的相关性分析[J]. 中国血液净化, 2020, 19(05): 289-293.
[7]	封蕾, 杨杰, 李萍, 李云姝, 陈客宏. 电子智能辅助工具改善透析患者营养不良及矿物质骨代谢异常的观察研究[J]. 中国血液净化, 2020, 19(05): 301-304.
[8]	袁美杰, 吴明, 叶朝阳. 不对称二甲基精氨酸在慢性肾脏病中的作用与机制研究进展[J]. 中国血液净化, 2020, 19(05): 327-329.
[9]	蒋易, 陆晓青, 梁献慧, 乔颖进, 王沛. 基层血液透析患者骨与矿物质代谢现状调查[J]. 中国血液净化, 2020, 19(04): 225-229.
[10]	刘必成, 李作林, 林善锬. 低氧诱导因子稳定剂在肾性贫血中的成功应用对未来的启示[J]. 中国血液净化, 2020, 19(03): 145-148.
[11]	赵璐, 刘虹. 慢性肾脏病患者的炎症状态及其对肾性贫血治疗的影响[J]. 中国血液净化, 2020, 19(03): 149-152.
[12]	蒲蕾, 王莉. 红细胞生成刺激因子低反应的原因分析及处理策略[J]. 中国血液净化, 2020, 19(03): 153-156.
[13]	陈静, 陈奕鸣, 杨晶, 李胜开, 孙京华, 蒋甘孺, 尹忠诚. 维持性血液透析患者血浆正五聚蛋白的变化与心血管事件危险因素的相关性[J]. 中国血液净化, 2020, 19(03): 183-186.
[14]	潘林蓉, 刘爽, 蒋更如. 慢性肾脏病患者生活质量评估方法与影响因素的研究现状[J]. 中国血液净化, 2020, 19(01): 49-51.
[15]	毕书红, 穆冰瑶, 唐子勇, 张爱华, 范敏华, 汪涛. 中国血液透析历史[J]. 中国血液净化, 2019, 18(11): 735-737.